CXCL10 and neoplasm: In mouse models, the DNMT inhibitor 5-azacytidine reactivated the expression of TH1-type chemokines (CXCL9 and CXCL10), increased infiltration of cytotoxic T-lymphocyte infiltration, and caused tumor regression in combination with anti-PD-L1 (91).